Weight loss surgery more effective than lifestyle management for type 2 diabetes

Publicly released:
International
CC-0. https://pixabay.com/images/search/weight%20loss/
CC-0. https://pixabay.com/images/search/weight%20loss/

US scientists say weight loss surgery is more effective than lifestyle management for long-term control of type 2 diabetes. They looked at outcomes around 10 years down the line for 262 people with type 2 diabetes who had either gone under the knife or received medical lifestyle management across four different studies. Those who had surgery had better blood sugar control, were less likely to be taking diabetes drugs, and were more likely to be in remission than those who tried managing their lifestyles, the researchers say. The results combined with existing evidence support the use of bariatric surgery for treatment of type 2 diabetes in people with obesity, they conclude.

Media release

From: JAMA

Long-Term Outcomes of Medical Management vs Bariatric Surgery in Type 2 Diabetes

About The Study: After 7 to 12 years of follow-up, individuals originally randomized to undergo bariatric surgery compared with medical/lifestyle intervention had superior glycemic control with less diabetes medication use and higher rates of diabetes remission. 

Attachments

Note: Not all attachments are visible to the general public. Research URLs will go live after the embargo ends.

Research JAMA, Web page The URL will go live after the embargo ends
Journal/
conference:
JAMA
Research:Paper
Organisation/s: University of Pittsburgh, USA
Funder: ARMMS-T2D is supported by cooperative agreement U01 DK114156 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Funding for the original trials were as follows: STAMPEDE was supported by an investigator-initiated grant from Ethicon Endo-Surgery and in-kind support from LifeScan and NIDDK grant R01 DK089547. TRIABETES was funded by NIDDK grants RC1DK086037 and R01 DK095128, and by subsidization of the surgical procedures byMagee-Womens Hospital of the University of Pittsburgh Medical Center. CROSSROADS was funded by NIDDK grant R01 DK089528, as well as by grants from the Group Health Research Institute and Group Health Foundation. The Shared Decision-Making aid used in this trial was provided by the Informed Medical Decisions Foundation. SLIMM-T2D was funded by NIDDK grants RC1 DK086918, R56 DK095451, and P30 DK036836; the Herbert Graetz Fund at Joslin Diabetes Center; and Patient-Centered Outcomes Research Institute grant CE-1304-6756. LifeScan, a division of Johnson & Johnson, provided home glucose-monitoring supplies; Nestle provided Boost; and Novo Nordisk provided drug supplies during the original trial. All 4 studies above received bridge funding from Covidien (now Medtronic) and Ethicon in preparation for the current NIH-funded observational follow-up and analysis.
Media Contact/s
Contact details are only visible to registered journalists.